OTCMKTS:GTSIF

Lobe Sciences Stock Forecast, Price & News

$0.09

0.00 (-4.01 %)

(As of 05/10/2021 03:52 PM ET)

Add

Compare

Today's Range

$0.09

▼

$0.11

50-Day Range

$0.09

▼

$0.18

52-Week Range

$0.02

▼

$0.22

Volume428,607 shs

Average Volume1.03 million shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive GTSIF News and Ratings via Email

Sign-up to receive the latest news and ratings for Lobe Sciences and its competitors with MarketBeat's FREE daily newsletter.

About Lobe Sciences

Lobe Sciences Ltd., a technology and services company, provides real estate, financial, management, intellectual property, and branding support for development of transformational medicine in the United States. The company intends to develop psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications. It also owns acquired brands, intellectual property, and leases office and production premises to a cannabis processor and retailer. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

Lobe Sciences to Present at the Benzinga Global Small Cap Conference
May 6, 2021 | finance.yahoo.com

Lobe Sciences Acquires Vitamind Line of Wellness Products
May 4, 2021 | finance.yahoo.com

Lobe Sciences Ltd.: Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin
April 30, 2021 | finanznachrichten.de

Lobe Sciences Announces Filing of PCT Application
April 29, 2021 | finance.yahoo.com

Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin
April 28, 2021 | finance.yahoo.com

Lobe Sciences Ltd. (OTCMKTS:GTSIF) Sees Significant Growth in Short Interest
April 28, 2021 | americanbankingnews.com

Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to Develop Multi-Sensory Pods for Clinical Psychedelic Use
April 27, 2021 | finance.yahoo.com

Lobe Sciences Appoints Benjamin Kelmendi, MD from Yale University to Scientific Advisory Board
April 20, 2021 | finance.yahoo.com

Lobe Sciences to Present at the Emerging Growth Conference on April 14, 2021
April 12, 2021 | finance.yahoo.com

Lobe Sciences Appoints Ilan Hayman to Advisory Board
April 6, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Drug Manufacturers—Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:GTSIF

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.greenstarbiosciences.com

Phone604-834-9499

EmployeesN/A

Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1994th out of 2,045 stocks

Drug Manufacturers—Specialty & Generic Industry

77th out of 84 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Lobe Sciences.

0.0 Community Rank

Outperform Votes
Lobe Sciences has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Lobe Sciences has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Lobe Sciences and other stocks. Vote “Outperform” if you believe GTSIF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GTSIF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Lobe Sciences does not currently pay a dividend.
Dividend Growth
Lobe Sciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lobe Sciences insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Lobe Sciences (OTCMKTS:GTSIF) Frequently Asked Questions

What stocks does MarketBeat like better than Lobe Sciences?

Wall Street analysts have given Lobe Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lobe Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lobe Sciences?

Lobe Sciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 39,800 shares, an increase of 255.4% from the March 31st total of 11,200 shares. Based on an average daily volume of 471,600 shares, the days-to-cover ratio is presently 0.1 days.
View Lobe Sciences' Short Interest.

Who are Lobe Sciences' key executives?

Lobe Sciences' management team includes the following people:

Mr. Jonathan R. Gilbert, Exec. Chairman (Age 50)
Mr. Philip J. Young, CEO, Corp. Sec. & Director (Age 64)
Mr. Brian Zasitko, Chief Financial Officer
Mr. Daniel S. McAtee, Chief Operating Officer (Age 55)
Mr. Maghsoud Dariani, Chief Science Officer (Age 68)

Who are some of Lobe Sciences' key competitors?

Some companies that are related to Lobe Sciences include (CSI) (CSI), 1933 Industries (TGIFF), 28896 (BAMM), 4Front Ventures (FFNTF), AB Science (ABSCF), Abattis Bioceuticals (ATT), Acreage (ACRHF), Acreage (ACRDF), AFT Pharmaceuticals (AFP), Agraflora Organics International (AGRA), AgraFlora Organics International (AGFAF), Aleafia Health (ALEAF), American Green (ERBB), Australian Primary Hemp (APH) and Ayr Wellness (AYRWF).
View all of GTSIF's competitors.

What is Lobe Sciences' stock symbol?

Lobe Sciences trades on the OTCMKTS under the ticker symbol "GTSIF."

How do I buy shares of Lobe Sciences?

Shares of GTSIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lobe Sciences' stock price today?

One share of GTSIF stock can currently be purchased for approximately $0.09.

What is Lobe Sciences' official website?

The official website for Lobe Sciences is www.greenstarbiosciences.com.

How can I contact Lobe Sciences?

The company can be reached via phone at 604-834-9499.

This page was last updated on 5/11/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Lobe Sciences Stock Forecast, Price & News

Adding

Adding

Adding Lobe Sciences Ltd.

About Lobe Sciences

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

0.0 Community Rank

Outperform Votes

Underperform Votes

0.0 Dividend Strength

Dividend Yield

Dividend Growth